QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

9Oct 2024

Driving innovation in Nordic SLD research🔍

Last week, Quantify’s Emilie Toresson Grip was invited to the first Swedish Steatotic Liver Disease (SLD) Think Tank, hosted by Karolinska Institutet.
24 hours packed with speed networking, group discussions, and insightful presentations.
The primary goals? Strengthening existing networks and fostering new connections across academia and industry.
The ultimate objective was to elevate Sweden and the Nordic countries’ position in international SLD research.

It’s an exhilarating time […]

7Oct 2024

Quantify is excited to attend the DIA RWE conference in Philadelphia!

Our CEO Kirk Geale, PhD will be attending the DRUG INFORMATION ASSOCIATION (DIA) Real-World Evidence conference in Philadelphia from October 24-25, 2024!

We are looking forward to meeting with clients and partners to showcase how our unique Nordic data can support global and US stakeholders with relevant and reliable RWE. Our highly transportable data has the power to answer research questions that […]

4Oct 2024

Health Economics Conference 2024 in Norway

Last week Quantify Research was present at the annual Health Economics Conference (Helseøkonomikonferansen) in Norway.

The conference gathered a broad audience and participation from academia, the healthcare sector, industry, patient organisations and government.
Over two days, the program was packed with presentations and discussions about hospital waiting times, the GP service, uncertainty and documentation in economic evaluation, perspectives and prioritisation in decision making, large public […]

2Oct 2024

Nordic RWE in FDA decision making

The use of Real-World Data (RWD) to support regulatory decisions is growing rapidly.
Several regulating agencies have in the past few years issued guidelines on the requirements on Real-World Evidence (RWE)-studies to be fit-for purpose for regulatory purposes.

Nordic data properties share many attributes, such as availability of key data elements, high data accuracy and almost universal completeness, highlighted by the recent FDA-guideline as key elements for RWD to be considered […]